CONFIDENTIAL TREATMENT REQUESTED BY INSITE VISION INCORPORATED— CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • October 7th, 2013 • Insite Vision Inc • Pharmaceutical preparations
Contract Type FiledOctober 7th, 2013 Company IndustryThis SECOND AMENDMENT TO LICENSE AGREEMENT (the “Second Amendment”) is made and effective as of June 13, 2013 (the “Second Amendment Effective Date”), by and between Inspire Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Merck Drive, Whitehouse Station, NJ 08889 (“Inspire”), and InSite Vision Incorporated, a Delaware corporation having its principal office at 965 Atlantic Ave., Alameda, CA 94501 (“InSite”). Inspire and InSite are each referred to herein as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED BY INSITE VISION INCORPORATED— CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 14th, 2013 • Insite Vision Inc • Pharmaceutical preparations
Contract Type FiledAugust 14th, 2013 Company IndustryThis SECOND AMENDMENT TO LICENSE AGREEMENT (the “Second Amendment”) is made and effective as of June 13, 2013 (the “Second Amendment Effective Date”), by and between Inspire Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at One Merck Drive, Whitehouse Station, NJ 08889 (“Inspire”), and InSite Vision Incorporated, a Delaware corporation having its principal office at 965 Atlantic Ave., Alameda, CA 94501 (“InSite”). Inspire and InSite are each referred to herein as a “Party” and collectively as the “Parties”.